An Open Label Phase I Trial of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Japanese Patients With Higher-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Trial Profile

An Open Label Phase I Trial of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Japanese Patients With Higher-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Volasertib (Primary) ; Azacitidine
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2015 Planned End Date changed from 1 Jun 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 11 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top